[go: up one dir, main page]

CY1122231T1 - Υποκατεστημενες 2-θειοξο-ιμιδαζολιδιν-4-ονες και σπειρο αναλογα αυτων, δραστικο αντικαρκινικο συστατικο, φαρμακευτικη συνθεση, φαρμακευτικο σκευασμα, μεθοδος για θεραπεια του καρκινου του προστατη - Google Patents

Υποκατεστημενες 2-θειοξο-ιμιδαζολιδιν-4-ονες και σπειρο αναλογα αυτων, δραστικο αντικαρκινικο συστατικο, φαρμακευτικη συνθεση, φαρμακευτικο σκευασμα, μεθοδος για θεραπεια του καρκινου του προστατη

Info

Publication number
CY1122231T1
CY1122231T1 CY20191100752T CY191100752T CY1122231T1 CY 1122231 T1 CY1122231 T1 CY 1122231T1 CY 20191100752 T CY20191100752 T CY 20191100752T CY 191100752 T CY191100752 T CY 191100752T CY 1122231 T1 CY1122231 T1 CY 1122231T1
Authority
CY
Cyprus
Prior art keywords
imidazolidin
thioxo
ones
substituted
treatment
Prior art date
Application number
CY20191100752T
Other languages
English (en)
Inventor
Alexandre Vasilievich IVACHTCHENKO
Original Assignee
R-Pharm Overseas Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R-Pharm Overseas Inc. filed Critical R-Pharm Overseas Inc.
Publication of CY1122231T1 publication Critical patent/CY1122231T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η εφεύρεση αφορά νέα (R)-στερεοϊσομερή υποκατεστημένων 2-θειοξο-ιμιδαζολιδιν-4-ονών του τύπου 1, ή σπειρο ανάλογα αυτών, τα οποία εμφανίζουν ιδιότητες ανταγωνιστή υποδοχέα ανδρογόνων, παραλλαγές μιας μεθόδου για παραγωγή αυτών και ενδιάμεσες ενώσεις για παραγωγή ενώσεων του τύπου 1. Οι ενώσεις του τύπου 1 μπορούν να χρησιμοποιηθούν για την παραγωγή ενός φαρμακευτικού παράγοντα, κατάλληλου για τη θεραπεία καρκίνων, όπως ο καρκίνος του προστάτη και ο καρκίνος του μαστού. Η εφεύρεση αφορά επίσης μια φαρμακευτική σύνθεση σε μορφή δισκίων, κάψουλων και ενέσεων. Στο τύπο 1, R1 είναι ΟΗ, ΝΗ2 ή μια OR4 ομάδα· R2 και R3 είναι μεθύλιο, ή R2 και R3 είναι μια CH2-CH2 ομάδα· R4 είναι C1-C4 αλκύλιο ή κυκλοπροπύλιο.
CY20191100752T 2014-07-08 2019-07-15 Υποκατεστημενες 2-θειοξο-ιμιδαζολιδιν-4-ονες και σπειρο αναλογα αυτων, δραστικο αντικαρκινικο συστατικο, φαρμακευτικη συνθεση, φαρμακευτικο σκευασμα, μεθοδος για θεραπεια του καρκινου του προστατη CY1122231T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2014127705/04A RU2557235C1 (ru) 2014-07-08 2014-07-08 Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты
PCT/RU2015/000395 WO2016007046A1 (ru) 2014-07-08 2015-06-26 Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты

Publications (1)

Publication Number Publication Date
CY1122231T1 true CY1122231T1 (el) 2020-11-25

Family

ID=53611746

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100752T CY1122231T1 (el) 2014-07-08 2019-07-15 Υποκατεστημενες 2-θειοξο-ιμιδαζολιδιν-4-ονες και σπειρο αναλογα αυτων, δραστικο αντικαρκινικο συστατικο, φαρμακευτικη συνθεση, φαρμακευτικο σκευασμα, μεθοδος για θεραπεια του καρκινου του προστατη

Country Status (23)

Country Link
US (1) US10450278B2 (el)
EP (1) EP3168214B1 (el)
JP (1) JP6581193B2 (el)
KR (1) KR102171120B1 (el)
AU (1) AU2015288381B2 (el)
CA (1) CA2954401C (el)
CY (1) CY1122231T1 (el)
DK (1) DK3168214T3 (el)
ES (1) ES2736507T3 (el)
GE (1) GEP20207096B (el)
HR (1) HRP20191265T8 (el)
HU (1) HUE044317T2 (el)
LT (1) LT3168214T (el)
PL (1) PL3168214T3 (el)
PT (1) PT3168214T (el)
RS (1) RS59009B1 (el)
RU (1) RU2557235C1 (el)
SI (1) SI3168214T1 (el)
SM (1) SMT201900379T1 (el)
TR (1) TR201910220T4 (el)
UA (1) UA117626C2 (el)
WO (1) WO2016007046A1 (el)
ZA (1) ZA201700922B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524711A (ja) * 2016-07-08 2019-09-05 ヤンセン ファーマシューティカ エヌ．ベー． アンドロゲン受容体アンタゴニストとしての置換ヒダントイン及びチオヒダントイン誘導体
CN107954936B (zh) * 2016-10-17 2021-03-19 海创药业股份有限公司 一种制备氘代咪唑二酮类化合物的方法
CN109422725A (zh) * 2017-09-04 2019-03-05 北京美倍他药物研究有限公司 前列腺癌治疗药物
RU2708253C2 (ru) * 2017-12-05 2019-12-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Новые производные арил-тиогидантоина, ингибиторы андрогенового рецептора, способ получения и применения
EP3897635A4 (en) 2018-12-19 2022-08-31 Celgene Corporation SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREOF
EP3897636B1 (en) * 2018-12-19 2024-12-11 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CN114621109B (zh) * 2020-12-14 2024-04-26 成都苑东生物制药股份有限公司 一种阿帕他胺的合成方法及其中间体
CN113698310B (zh) * 2021-08-20 2023-03-17 江西金丰药业有限公司 一种恩杂鲁胺双酯中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2444085E (pt) * 2005-05-13 2015-06-11 Univ California Compostos de diaril-hidantoínas como antagonistas do recetor androgénio para tratamento de cancro
EP2400847B1 (en) * 2009-02-24 2014-12-17 Medivation Prostate Therapeutics, Inc. Specific diarylthiohydantoin compounds
EP3357917A1 (en) * 2010-02-16 2018-08-08 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
ES2671343T3 (es) * 2010-02-24 2018-06-06 Medivation Prostate Therapeutics Llc Procesos para la síntesis de compuestos de diariltiohidantoína y diarilhidantoína
RU2434851C1 (ru) * 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
RU2520134C1 (ru) * 2013-02-27 2014-06-20 Общество с ограниченной ответственностью "Авионко" (ООО "Авионко") Замещенные (r)-3-(4-метилкарбамоил-3-фторфениламино)-тетрагидро-фуран-3-енкарбоновые кислоты и их эфиры, способ их получения и применения

Also Published As

Publication number Publication date
RU2557235C1 (ru) 2015-07-20
PL3168214T3 (pl) 2019-10-31
CA2954401A1 (en) 2016-01-14
SMT201900379T1 (it) 2019-09-09
ES2736507T3 (es) 2020-01-02
US10450278B2 (en) 2019-10-22
DK3168214T3 (da) 2019-07-22
EP3168214B1 (en) 2019-04-24
EP3168214A1 (en) 2017-05-17
SI3168214T1 (sl) 2019-09-30
UA117626C2 (uk) 2018-08-27
AU2015288381A1 (en) 2017-03-02
HRP20191265T1 (hr) 2019-10-18
AU2015288381B2 (en) 2019-11-07
HUE044317T2 (hu) 2019-10-28
US20180179164A1 (en) 2018-06-28
TR201910220T4 (tr) 2019-07-22
PT3168214T (pt) 2019-07-25
RS59009B1 (sr) 2019-08-30
JP2017522379A (ja) 2017-08-10
ZA201700922B (en) 2019-08-28
KR102171120B1 (ko) 2020-10-29
EP3168214A4 (en) 2018-02-14
CA2954401C (en) 2021-03-02
KR20170023184A (ko) 2017-03-02
WO2016007046A1 (ru) 2016-01-14
LT3168214T (lt) 2019-07-25
GEP20207096B (en) 2020-04-10
HRP20191265T8 (hr) 2019-11-01
JP6581193B2 (ja) 2019-09-25

Similar Documents

Publication Publication Date Title
CY1122231T1 (el) Υποκατεστημενες 2-θειοξο-ιμιδαζολιδιν-4-ονες και σπειρο αναλογα αυτων, δραστικο αντικαρκινικο συστατικο, φαρμακευτικη συνθεση, φαρμακευτικο σκευασμα, μεθοδος για θεραπεια του καρκινου του προστατη
CY1123649T1 (el) Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
ECSP18090144A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
MY195977A (en) Heterocyclic Compounds and uses Thereof
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
NZ721617A (en) Heterocyclic compounds
MX372716B (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
CO2020007222A2 (es) Proceso para la preparación de derivados antihelmínticos de 4-amino-quinolin-3-carboxamida
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
DOP2017000034A (es) Compuestos de imidazopiridazina
CY1120680T1 (el) Ανταγωνιστες η3 που περιεχουν συνταξη πυρηνα φαινοξυπιπεριδινης
PH12016500322A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
CR20170468A (es) Compuestos novedosos
CY1122172T1 (el) Τροποποιητες θειαζολης των a3 υποδοχεων αδενοσινης
TR201819805T4 (tr) Flavaglin türevleri̇.
CR20160373A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
CY1119984T1 (el) Σταθεροποιημενη αμορφη μορφη αγομελατινης, μια μεθοδος για την παρασκευη της και φαρμακευτικες συνθεσεις που την περιεχουν
MX2018015269A (es) Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos.